Recent Updates
Recently added Catalysts
AKBA Positive Sentiment

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

Wednesday, December 18, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Akebia Therapeutics announced that CEO John Butler will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2024. During the presentation, he will provide updates on the company's initiatives, including the U.S. launch of Vafseo (vadadustat). The conference is scheduled for January 13-16, 2025, in San Francisco.
Price reaction · baseline $1.87 (2024-12-17 close) · hit after-hours · clean, no other AKBA news in the window
day 0 close · peak
-5.9%
day 1
-4.3%
day 3
-1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Akebia Therapeutics is actively participating in a major healthcare conference.
  • The CEO will discuss the U.S. launch of Vafseo, indicating progress.
  • The company aims to improve the lives of those affected by kidney disease.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+1%
120-day peak, hindsight
Typical move
8%
average across 4 past catalysts
Lead asset
ferric
Phase 3 · Anemia of Chronic Kidney Disease

Full Press Release Details

CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA ), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler , Chief Executive Officer, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2024 at 7:30 AM PST . Among other business updates, Mr. Butler will discuss the Vafseo® (vadadustat) U.S. launch.
A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference.
The J.P. Morgan Healthcare Conference will take place January 13-16, 2025 in San Francisco .
About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts . For more information, please visit our website at www.akebia.com , which does not form a part of this release.
Akebia Therapeutics Contact Mercedes Carrasco [email protected]

Frequently Asked Questions

When will Akebia present at the J.P. Morgan Conference?

Akebia will present on January 16, 2024, at 7:30 AM PST.

What will Akebia's CEO discuss at the conference?

CEO John Butler will discuss the U.S. launch of Vafseo (vadadustat).

Where can I watch the Akebia presentation?

The presentation will be available via webcast on Akebia's website.

What is the purpose of Akebia Therapeutics?

Akebia aims to improve the lives of people impacted by kidney disease.

ShareAdd on Google
Tags: AKBA Viatris Investor Conferences Healthcare Akebia Therapeutics J.P. Morgan Healthcare Conference Vafseo vadadustat kidney disease
Last updated: Dec 18, 2024

Biotech snapshot

Cash runway
$156M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ferricPhase 3
Anemia of Chronic Kidney Disease →

Catalyst track record

+1%
best trade around AKBA's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for AKBA.

See every catalyst's timing & PoA →